ADCT News and Press, ADC Therapeutics SA

LAUSANNE, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will present a company overview at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 11:30 a.m. ET. A live webcast of th...

LAUSANNE, Switzerland, May 15, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ on Monday, May 20, 2024 at 2:00 p.m. ...

2024-05-14 13:21:15 ET More on ADC Therapeutics ADC Therapeutics: Real Opportunity With Real Risk In 2024 (Rating Upgrade) ADC Therapeutics gains after data for lymphoma therapy ADC Therapeutics SA (ADCT) Q1 2024 Earnings Call Transcript ADC Therapeutics SA 2...

LAUSANNE, Switzerland, May 09, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference on Tuesday, May 14, 2024, at 1:35 p.m. ET. A ...

2024-05-06 11:04:07 ET ADC Therapeutics SA (ADCT) Q1 2024 Earnings Conference Call May 06, 2024 08:30 A.M. ET Company Participants Nicole Preiss-Riley - Executive Director, Head of Communications Ameet Mallik - CEO Kristen Herrington-Smith - Chief Commercial Offi...

2024-05-06 07:53:53 ET More on ADC Therapeutics ADC Therapeutics: Real Opportunity With Real Risk In 2024 (Rating Upgrade) ADC Therapeutics gains after data for lymphoma therapy Seeking Alpha’s Quant Rating on ADC Therapeutics Read the full article o...

LAUSANNE, Switzerland, May 06, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it has agreed to sell, by way of an underwritten offering, 13,411,912 of its common shares at a price of $4.900 per share and, to certain investors who so choose in lieu of common shares,...

PRA Group Inc. (PRAA) is expected to report $-0.15 for Q1 2024 Bowman Consulting Group Ltd. (BWMN) is expected to report $-0.04 for Q1 2024 Noble Corporation plc A (NE) is expected to report $0.56 for Q1 2024 Velo3D Inc. (VLD) is expected to report for Q3 2024 Axon Enterprise Inc....

2024-05-06 06:13:21 ET More on ADC Therapeutics ADC Therapeutics: Real Opportunity With Real Risk In 2024 (Rating Upgrade) ADC Therapeutics gains after data for lymphoma therapy Seeking Alpha’s Quant Rating on ADC Therapeutics Read the full article o...

ZYNLONTA ® (loncastuximab tesirine-lpyl) net sales of $17.8 million in 1Q 2024; total operating expenses decreased 25% (adjusted total operating expenses decreased 16%) 1 compared to 1Q 2023 Successfully completed LOTIS-7 dose escalation and initiated expansion in 2...